Four-year follow-up of the randomised comparison between an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II trial).

Chevalier, Bernard; Cequier, Angel; Dudek, Dariusz; Haude, Michael; Carrie, Didier; Sabaté, Manel; Windecker, Stephan; Reith, Sebastian; de Sousa Almeida, Manuel; Campo, Gianluca; Iñiguez, Andres; Onuma, Yoshi; Serruys, Patrick W (2018). Four-year follow-up of the randomised comparison between an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II trial). EuroIntervention, 13(13), pp. 1561-1564. Europa Digital & Publishing 10.4244/EIJ-D-17-00873

[img] Text
128th_issue-article_251.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (584kB) | Request a copy

AIMS

No randomised comparison data are available beyond the resorption of the everolimus-eluting bioresorbable scaffold. Absorb is expected to be completely resorbed by 3 years. The purpose of this report is to provide the 4 year results of a randomised, single blind, multicentre evaluation of Absorb versus the metallic stent Xience (Abbott Vascular, Santa Clara, CA, USA).

METHODS AND RESULTS

Three-year follow-up has been previously published. Patients re-consented for additional follow-up up through to 5 years; 86% (N=289) and 84% (N=139) of whom underwent a 4 year follow-up visit. TLF was noted in 11.5% in the Absorb arm and 6.0% in the Xience arm (p=0.063) at 4 years, with 1.0% and 0.7% absolute difference respectively between 3 and 4 years. No new very late definite/probable scaffold/stent thrombosis was reported between 3 and 4 years, with a 4-year rate of 3.0% versus 0.0% (p=0.035) and a slight decrease in DAPT prescription in both arms at 4 years (25.9% versus 21.1%, p=NS).

CONCLUSIONS

A downturn of events was recorded beyond the expected resorption time. Further long-term evaluation in larger randomised studies is necessary to confirm this observation.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Cardiology

UniBE Contributor:

Windecker, Stephan

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1774-024X

Publisher:

Europa Digital & Publishing

Language:

English

Submitter:

Nadia Biscozzo

Date Deposited:

12 Apr 2018 10:52

Last Modified:

05 Dec 2022 15:08

Publisher DOI:

10.4244/EIJ-D-17-00873

PubMed ID:

29094677

BORIS DOI:

10.7892/boris.107402

URI:

https://boris.unibe.ch/id/eprint/107402

Actions (login required)

Edit item Edit item
Provide Feedback